Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MDNA.TO
- Price
- 0.95
- Stock movement up
- +0.05 (5.56%)
- Company name
- Medicenna Therapeutics Corp
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 74.25M
- Ent value
- 56.70M
- Price/Sales
- 14850.00
- Price/Book
- 3.70
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 17.30%
- 1 year return
- -51.53%
- 3 year return
- -15.95%
- 5 year return
- -23.13%
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
MDNA.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 14850.00 |
| Price to Book | 3.70 |
| EV to Sales | 11340.20 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 78.16M |
| EPS (TTM) | -0.35 |
| FCF per share (TTM) | -0.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.00K |
| Gross profit (TTM) | 2.00K |
| Operating income (TTM) | -12.82M |
| Net income (TTM) | -26.68M |
| EPS (TTM) | -0.35 |
| EPS (1y forward) | -0.24 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 40.00% |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 30.43M |
| Net receivables | 1.49M |
| Total current assets | 32.68M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 32.93M |
| Accounts payable | 1.99M |
| Short/Current long term debt | 176.00K |
| Total current liabilities | 2.87M |
| Total liabilities | 12.88M |
| Shareholder's equity | 20.05M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -16.81M |
| Capital expenditures (TTM) | 33.00K |
| Free cash flow (TTM) | -16.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -133.06% |
| Return on Assets | -81.03% |
| Return on Invested Capital | -132.85% |
| Cash Return on Invested Capital | -83.87% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.93 |
| Daily high | 0.96 |
| Daily low | 0.92 |
| Daily Volume | 26K |
| All-time high | 7.00 |
| 1y analyst estimate | 4.38 |
| Beta | 1.19 |
| EPS (TTM) | -0.35 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 25 Jun 2025 |
Downside potential
Loading...
Downside potential data
| MDNA.TO | S&P500 | |
| Current price drop from All-time high | -86.43% | -12.04% |
| Highest price drop | -96.86% | -56.47% |
| Date of highest drop | 1 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -58.38% | -11.07% |
| Avg time to new high | 67 days | 12 days |
| Max time to new high | 1224 days | 1805 days |
COMPANY DETAILS
Marketcap
74.25M
Marketcap category
Small-cap
Description
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Employees
16
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the dev...
April 1, 2025
Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, MDN...
March 26, 2025
Medicenna Therapeutics (MDNA.TO) on Tuesday said new data from its ABILITY-1 study show a "significa
February 25, 2025
MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a 30% ...
February 25, 2025
Medicenna Therapeutics (MDNA.TO) was last seen 12% after the company on Thursday said its third-quar
February 13, 2025
- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 t...
February 13, 2025
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
February 5, 2025
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse m...
December 13, 2024
Medicenna Therapeutics (MDNA) on Thursday said updated and promising clinical data from its Phase 1/
December 5, 2024
70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and Canad...
December 5, 2024
Next page